IP Library Granted Patent US 9,176,145
Granted Patent B2
US 9,176,145 · App. 13/539,660 · Granted Nov 3, 2015

Kit for predicting implantation success in assisted fertilization

Inventors: Nathalie Lédée (Poissy, FR); Marie-Pierre Piccinni (Florence, IT)
Assignee: FEMALON S.P.R.L.
G01N33/689C12Q1/6876C12Q1/6883G01N33/6863C12Q2600/158G01N2333/535
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,176,145
App. No.
13/539,660
Granted
Nov 3, 2015
Kind
B2
Abstract

A kit for determining for a female subject the implantation potential of embryos obtained or to be obtained by assisted fertilization is described. The kit includes at least one reagent suitable for detection of levels of FF G-CSF or FF G-CSF mRNA, such as anti-G-CSF antibody or a nucleic acid probe for detection of levels of G-CSF mRNA. The kit may also include a set of concentration standards of FF G-CSF and aspirator tips for removing an oocyte and follicular fluid.

Claims (9)

1. A kit for determining for a female subject the implantation potential of embryos obtained or to be obtained by assisted fertilization comprising:

system for measuring for a plurality of oocytes collected from said subject the level of follicular fluid granulocyte-colony stimulating factor (G-CSF) present in the follicular fluid (FF) of a follicle of each collected oocyte, which system comprises at least one reagent suitable for detection of levels of FF G-CSF or FF G-CSF mRNA, and

a plurality of disposable aspirator tips for removing an oocyte and follicular fluid from a subject.

2. Kit according claim 1 , further comprising a set of concentration standards of G-CSF.

3. Kit according claim 2 , wherein the concentration standards are commercial G-CSF standards.

4. Kit according to claim 1 , wherein the at least one reagent comprises an anti-G-CSF antibody for detection of levels of FF G-CSF.

5. Kit according to claim 4 , wherein the anti-G-CSF antibody is labeled.

6. Kit according to claim 1 , wherein the reagent is a nucleic acid probe for detection of levels of G-CSF mRNA.

7. Kit according to claim 6 , wherein the nucleic acid probe is labeled.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: LEDEE, NATHALIE; PICCINNI, MARIE-PIERRE
To: MITHRA PHARMACEUTICALS NV/SA
Reel/Frame 036860/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: MITHRA PHARMACEUTICALS NV/SA
To: FEMALON S.A.
Reel/Frame 036860/0765 →
CHANGE OF NAME Recorded Apr 1, 2014
From: FEMALON S.A.
To: FEMALON S.P.R.L.
Reel/Frame 032589/0125 →
CHANGE OF ADDRESS Recorded Apr 1, 2014
From: FEMALON S.P.R.L.
To: FEMALON S.P.R.L.
Reel/Frame 032589/0131 →
Continuity (3)
Continuation In Part 12374472
Provisional Application 60832094 · Jul 21, 2006
Related Publication 20120283673A1 · Nov 8, 2012